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Abstract
Background: The status of estrogen receptor-a (ERa) is critical to the clinical prognosis and therapeutic approach
in breast cancer. ERa-negative breast cancer is clinically aggressive and has a poor prognosis because of the lack
of hormone target-directed therapies. Previous studies have shown that epigenetic regulation plays a major role in
ERa silencing in human breast cancer cells. Dietary green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), is
believed to be an anticancer agent in part through its regulation of epigenetic processes.
Results: In our current studies, we found that EGCG can reactivate ERa expression in ERa-negative MDA-MB-231
breast cancer cells. Combination studies using EGCG with the histone deacetylase (HDAC) inhibitor, trichostatin A
(TSA), revealed a synergistic effect of reactivation of ERa expression in ERa-negative breast cancer cells.
Reactivation of ERa expression by EGCG and TSA treatment was found to sensitize ERa-dependent cellular
responses to activator 17b-estradiol (E2) and antagonist tamoxifen in ERa-negative breast cancer cells. We also
found that EGCG can lead to remodeling of the chromatin structure of the ERa promoter by altering histone
acetylation and methylation status thereby resulting in ERa reactivation. A decreased binding of the transcription
repressor complex, Rb/p130-E2F4/5-HDAC1-SUV39H1-DNMT1, in the regulatory region of the ERa promoter also
contributes to ERa transcriptional activation through treatment with EGCG and/or TSA.
Conclusions: Collectively, these studies show that green tea EGCG can restore ERa expression by regulating
epigenetic mechanisms, and this effect is enhanced when combined with an HDAC inhibitor. This study will
facilitate more effective uses of combination approaches in breast cancer therapy and will help to explore more
effective chemotherapeutic strategies toward hormone-resistant breast cancer.
Background
Numerous experimental and clinical studies have estab-
lished that the clinical outcome of chemotherapeutic
strategies for breast cancer commonly rely on the
expression of important growth factor receptors such as
the nuclear estrogen receptors (ERs) [1]. ERs mediate
effects of estrogen hormone such as 17b-estradiol (E2)
through a ligand-receptor binding activated signal path-
way leading to cellular proliferation and differentiation
in normal mammary tissue [2]. The status of ERs also
plays an important role in monitoring of the malignant
behavior of breast cancer. Of the two major isoforms of
ERs (ERa and ERb) that have been identified to date,
however, the ERa isoform is believed to primarily con-
tribute to estrogen induced growth-stimulatory effects in
breast cancer [3]. For the tumors that express ERa,
therapeutic strategies include estrogen ablation or anti-
estrogens. However, ERa-negative breast cancers have
more clinically aggressive biological characteristics and
the prognosis is poor because of the lack of target-direc-
ted therapies [4].
It has been known that the absence of ERa gene
expression in ERa-negative breast cancer is not due to
DNA mutations of the ERa gene [5]. Therefore,
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mechanism for hormone resistance in ERa-negative
breast cancer. Previous studies have shown that more
than 25% of ERa-negative breast cancer cells have an
aberrant methylation status of the ERa promoter [6-8].
In addition, histone acetylation/deacetylation has also
been implicated as a common mechanism underlying
ERa gene trans-activation/repression in human malig-
nant mammary cells [9]. Correspondingly, DNA methyl-
tranferase (DNMT) inhibitors such as 5-aza-2’-
deoxycytidine (5-aza) and histone deacetylase (HDAC)
inhibitors like trichostatin A (TSA) have been success-
fully used to induce ER expression and sensitize hor-
mone-resistant ERa-negative breast cancer cells to
chemotherapy [8,10-12]. In this regard, it is increasingly
evident that epigenetic events play an important role in
ERa gene expression.
Epigallocatechin-3-gallate (EGCG), a major polyphenol
in green tea, has been extensively studied as a bioactive
dietary component against various types of carcinomas
through multiple mechanisms such as anti-oxidation,
induction of apoptosis, inhibition of angiogenesis and
metastasis [13]. It has been shown that EGCG can pre-
vent and inhibit breast tumorigenesis independently of
ER status [14,15]. Moreover, EGCG enhanced tamoxi-
fen-induced cellular apoptosis in ERa-negative MDA-
MB-231 breast cancer cells suggesting that EGCG may
impart its anti-cancer property through a unique
mechanism acting on ERa signal transduction [16].
However, the precise molecular mechanisms underlying
this phenomenon are still unclear. Recently, one poten-
tial mechanism that has received considerable attention
is that EGCG can modulate gene expression by influen-
cing epigenetic processes such as DNA methylation
and/or histone modification [17,18]. Studies have shown
that EGCG can alter DNA methylation patterns in
human cancer cells as well as mouse models and by
directly and indirectly inhibiting the enzymatic activities
of DNA methyltransferases (DNMTs) [18,19]. This
effect results in reactivation of methylated-silencing
tumor suppressor genes such as p16
INK4a , retinoic acid
receptor b (RARb), and the DNA mismatch repair gene
human mutL homologue 1 (hMLH1) which collectively
leads to tumor suppression [18]. Furthermore, it is
believed that EGCG-induced remodeling of chromatin
structure is a key epigenetic mechanism for regulating
tumor-related gene transcription. Consistently, our pre-
vious studies also found that the green tea polyphenol,
EGCG, can influence patterns of histone acetylation in
the human telomerase reverse transcriptase (hTERT)
promoter, which leads to hTERT transcription inhibition
and tumor suppression in malignant human mammary
cells [17]. Since estrogen-resistant breast cancers pose a
major risk to breast cancer patients, we asked whether
EGCG may facilitate the epigenetic processes leading to
ERa re-expression in ERa-negative breast cancer cells
and whether combination epigenetic approaches may
have synergistic effects in these cells.
Our studies were aimed to address the epigenetic
mechanisms of ERa reactivation by EGCG in hormone-
resistant breast cancer cells. In the present studies, we
analyzed the epigenetic mechanisms of ERa re-expres-
sion and corresponding ERa-stimulated signal pathway
in ERa-negative MDA-MB-231 cells treated with
EGCG. In addition, by applying two epigenetic modula-
tors including the HDAC inhibitor, TSA and the
demethylation agent, 5-aza, we were able to investigate
the epigenetic mechanisms of ERa-reactivation and to
explore the applicability of this or similar combination
to breast cancer therapy. We found, for the first time,
that EGCG and TSA can synergistically reactivate ERa
expression and thus, activate the ERa binding-induced
cellular signal pathway through epigenetic control. Clini-
cally, this reactivation of ERa enhances chemosensitivity
to tamoxifen, an anti-estrogen drug, in ERa-negative
breast cancer cells, suggesting a potential clinical thera-
peutical application of combination of EGCG with a his-
tone deacetylase inhibitor in breast cancer. Our findings
help to assess the key mechanisms of EGCG chemopre-
vention and therapy by impacting epigenetic pathways.
Moreover, it will open new avenues to manage a subset
of estrogen-resistant breast cancers and improve the
survival rate in breast cancer by using these compounds,
especially in combination.
Materials and methods
Cell culture and cell treatment
The ERa-positive MCF-7 and ERa-negative MDA-MB-
231 breast cancer cell lines were obtained from American
Type Culture Collection (ATCC). Cells were grown in
phenol-red-free medium DMEM (Invitrogen, Carlsbad,
CA) supplemented with 10% dextran-charcoal-stripped
fetal bovine serum (Atlanta Biologicals, Lawrenceville,
GA) and 1% penicillin/streptomycin (Mediatech, Hern-
don, VA). Cells were maintained in a humidified environ-
ment of 5% CO2 and 95% air at 37°C. To evaluate ERa
expression, MDA-MB-231 cells were treated with various
concentrations of EGCG (Sigma, St. Louis, MO) for 3
days while MCF-7 cells served as a positive control. The
medium with EGCG was replaced every 24 h for the
duration of the experiment. Control cells received equal
amounts of DMSO (Sigma) in the medium. For the com-
bination study, cells were treated with an optimal con-
centration (10 μM) of EGCG based on our following
results and 5-aza (2 μM for 2 days) (Sigma) or TSA (100
ng/ml for 12 h) (Sigma) alone or together for a total 3
days as the common recommended doses of these com-
pounds [12].
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To determine the effects of ERa reactivation on cellular
proliferation induced by EGCG, ERa-negative MDA-
MB-231 and positive control MCF-7 cells were seeded
in triplicate in 24-well plates. To determine the optimal
concentration of EGCG on ERa expression, MDA-MB-
231 cells were treated with various concentrations of
EGCG. For the combination study, MDA-MB-231 cells
were treated with 10 μME G C Ga n d2μM 5-aza or 100
ng/ml TSA alone or together for 3 days. To observe the
effects of 17b-estradiol (E2) (Sigma) and tamoxifen
(Sigma) on ERa expression, EGCG and/or TSA-pre-
treated MDA-MB-231 cells were then exposed with/
without 10 nM of E2 or 1 μM tamoxifen [12] for an
extra two days, respectively. To determine cell viability,
cells were trypsinized and resuspended in PBS (Phos-
phate buffered saline) buffer. Equal volumes of Trypan
blue (0.4%) and cell suspensions were mixed and incu-
bated at room temperature for 10 min. Both viable
(unstained) and nonviable (stained) cells were counted
using a hemacytometer. The percentages of viable cells
were calculated by the formula: Viable cells (%) = num-
ber of viable cells per ml of aliquot/number of total
cells per ml of aliquot × 100.
Quantitative real-time PCR
Both ERa-positive MCF-7 and ERa-negative MDA-MB-
231 cells were cultured and treated as described above.
Total RNA was extracted using the RNeasy kit (Qiagen,
Valencia, CA) according to the manufacturer’si n s t r u c -
tions. Genes of interest were amplified using 5 μgo f
total RNA reverse transcribed to cDNA using the Super-
script II kit (Invitrogen) with oligo-dT primer. In the
real-time PCR step, PCR reactions were performed in
triplicate with 1 μl cDNA per reaction and primers spe-
cific for ERa (Hs01046818_ml), progesterone receptor
(PGR) (Hs01556702_ml) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) (Hs99999905_ml) pro-
vided by Inventoried Gene Assay Products (Applied
Biosystems, Foster City, CA) using the Platinum Quanti-
tative PCR Supermix-UDG (Invitrogen) in a Roche
LC480 thermocycler. Thermal cycling was initiated at
94°C for 4 min followed by 35 cycles of PCR (94°C, 15
s; 60°C, 30 s). GAPDH was used as an endogenous con-
trol, and vehicle control was used as a calibrator. The
relative changes of gene expression were calculated
using the following formula: fold change in gene expres-
sion, 2
-ΔΔCt =2
-{ΔCt (treated samples) - ΔCt (untreated control
samples)},w h e r eΔCt = Ct (ERa or PGR) - Ct (GAPDH)
and Ct represents threshold cycle number.
Western blot analysis
For western blot analysis, protein extracts were pre-
pared by RIPA Lysis Buffer (Upstate Biotechnology,
Charlottesville, VA) according to the manufacturer’s
protocol. Proteins (100 μg) were electrophoresed on a
10% SDS-polyacrylamide gel and transferred to nitro-
cellulose membranes. Membranes were probed with
antibodies to ERa (6F11; NeoMarkers, Fremont, CA),
HDAC1 (H11; Santa Cruz Biotechnology), p300 (C-20;
Santa Cruz Biotechnology) and SUV39H1 (44.1; Santa
Cruz Biotechnology), then each membrane was
stripped and reprobed with GAPDH antibody (V-18,
Santa Cruz Biotechnology) as loading control. Molecu-
lar weight markers were run on each gel to confirm
the molecular size of the immunoreactive proteins.
Immunoreactive bands were visualized using the
enhanced chemiluminescence detection system (Santa
Cruz Biotechnology) following the protocol of the
manufacturer.
Chromatin Immunoprecipitation (ChIP) assay
MDA-MB-231 cells were treated with 10 μM EGCG and
100 μg/ml TSA alone or in combination for the indi-
cated times. Approximately 2 × 10
6 cells were cross-
linked with a 1% final concentration of formaldehyde
(37%, Fisher Chemicals, Fairlawn, NJ) for 10 min at
37°C. ChIP assays were performed with the EZ-Chroma-
tin Immunoprecipitation (EZ-ChIP™) assay kit according
to the manufacturer’s protocol (Upstate Biotechnology)
as described previously [20]. The epigenetic antibodies
used in the ChIP assays were ChIP-validated acetyl-his-
tone H3 (Upstate Biotechnology), acetyl-histone H3-
Lys9 (H3K9) (Upstate Biotechnology), acetyl-histone H4
(Upstate Biotechnology), histone deacetylase1 (HDAC1)
(Santa Cruz Biotechnology), p300 (Santa Cruz Biotech-
nology), SUV39H1 (Santa Cruz Biotechnology),
dimethyl-histone H3-Lys4 (H3K4) (Upstate Biotechnol-
ogy), trimethyl-histone H3-Lys9 (H3K9) (Upstate Bio-
technology) and DNMT1 (Abcam, Cambridge, MA).
The transcription factor antibodies in this study were
E2F4 (RK-13; Santa Cruz Biotechnology) and Rb/p130
(C-20; Santa Cruz Biotechnology). ChIP-purified DNA
was amplified by standard PCR using primers specific
for the ERa promoter yielding a 150 bp fragment: sense,
5’-GAACCGTCCGCAGCTCAAGATC-3’ and anti-
sense, 5’-GTCTGACCGTAGACCTGCGCGTTG-3’.
PCR amplification was performed using the 2 × PCR
Master Mix (Promega, Madison, WI) and the reaction
was initiated at 94°C for 4 min followed by 30 cycles of
PCR (94°C, 30 s; 56°C, 30 s; 72°C, 1 min), and extended
at 72°C for 5 min. After amplification, PCR products
were separated on 1.5% agarose gels and visualized by
ethidium bromide fluorescence using Kodak 1D 3.6.1
image software (Eastman Kodak Company, Rochester,
NY). Quantitative data were analyzed using the
Sequence Detection System software version 2.1 (PE
Applied Biosystems, Foster City, CA).
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Cultured MDA-MB-231 cells were harvested at the indi-
cated time points as described above, and nuclear
extracts were prepared with the nuclear extraction
reagent (Pierce, Rockford, IL). The activities of histone
deacetylases, HDACs (Active Motif, Carlsbad, CA), and
histone acetyltransferases, HATs (Epigentek, Brooklyn,
NY), were performed according to the manufacturer’s
protocols as reported previously [21]. The enzymatic
activities of HDACs and HATs were detected by a
microplate reader at 450 nm.
Bisulfite sequencing analysis
The DNA methylation status of the ERa promoter was
detected by sodium bisulfite methylation sequencing.
Approximately 1 μg genomic DNA was treated with
bisulfite following the manufacture’s protocol (Human
Genetic Signatures, Macquarie Park, Australia). Bisul-
fite-modified DNA was amplified using two primer sets
spanning a region from -66 to +356 of the ERa core
promoter. PCR amplifications were performed with pri-
mers sense, 5’-AGTATTTTT GTAATGTATAT-3’,a n d
antisense, 5’-TCCAAATAATAAAACACCTA-3’.P C R
products were purified using a gel extraction kit (Qia-
gen) and were directly cloned in pGEM-T vector
according to manufacturer’s protocol of pGEM-T Easy
Vector Systems (Promega). Purified plasmids were
sequenced with sense primer on an automated DNA
sequencer. Each sample was sequenced on more than
five clones to determine the site-specificm e t h y l a t i o n
changes in the ERa promoter region.
Statistical analyses
Data from Real-time PCR and luciferase assays were
derived from at least three independent experiments.
For quantification of ChIP products, Kodak 1D 3.6.1
image software was used. The protein levels were quan-
tified by optical densitometry using ImageJ Software ver-
sion 1.36b http://rsb.info.nih.gov/ij/. Statistical
significance between treatment and control groups was
evaluated using Mann-Whitney U test. P <0 . 0 5w a s
considered significant.
Results
EGCG acts synergistically with TSA in reactivating ERa
expression in ERa-negative MDA-MB-231 breast cancer
cells
To elucidate the effects of the green tea polyphenol,
EGCG, on cellular viability and ERa expression in ERa-
negative MDA-MB-231 breast cancer cells, we initiated
to determine the optimal dose that will induce ERa
transcriptional activation without causing toxicity to
cells. The Trypan blue exclusion assay was performed
with the MDA-MB-231 cells treated with various
concentrations of EGCG as shown in Figure 1A. In
accordance with previous findings, we found that cellu-
lar growth was inhibited with EGCG treatment in a
dose-dependent manner in MDA-MB-231 cells, which
became significant at 25 μMa n d5 0μM of EGCG. In
addition, in Figure 1C a significant increased expression
of endogenous ERa transcription (p < 0.05) was
observed with the relatively low dose of 10 μMo f
EGCG treatment at which concentration no significant
cellular growth inhibition was found. To further deter-
mine whether 10 μM is the optimal concentration of
EGCG treatment on ERa reactivation, we included three
extra concentrations such as 7.5, 15 and 20 μMo f
EGCG to compare ERa expression under these concen-
trations with ERa at 10 μM of EGCG. As shown in Fig-
ure 1D, EGCG treatment at 10 μMs t i l le x h i b i t e d
capability to induce the maximal expression of ERa
expression compared with the additional concentrations
of EGCG suggesting 10 μM of EGCG is the optimal
concentration to induce ERa reactivation in ERa-nega-
tive MDA-MB-231 breast cancer cells. However, there is
no obvious dose-dependent manner on ERa expression
with EGCG treatment suggesting a precise amount of
EGCG is required to obtain the maximal effect on ERa
expression in ERa-negative breast cancer cells [22].
These results indicated that the low concentration of 10
μM EGCG that does not induce cellular toxicity, has a
potential bioavailability towards chemoprevention and
therapy through regulating ERa re-expression in ERa-
negative breast cancer cells. Based on these results, we
therefore chose to use the concentration of 10 μM
EGCG in our subsequent studies.
Previous studies have shown that epigenetic mechan-
isms involving both DNA methylation and histone mod-
ification contribute to regulation of ERa expression. To
verify the epigenetic roles on ERa expression, a combi-
nation study was performed by using two important epi-
genetic agents including the histone deacetylase (HDAC)
inhibitor, trichostatin A (TSA), and a demethylation
agent, 5-aza-2’-deoxycytidine (5-aza), with EGCG treat-
ment in ERa-negative MDA-MB-231 breast cancer cells.
Both TSA and 5-aza have been reported to successfully
activate ERa t r a n s c r i p t i o ni nh u m a nE R a-negative
breast cancer cells, but have not previously been com-
bined with EGCG in ER studies [8]. Our results indi-
cated that EGCG alone reactivates ERa expression and
that EGCG with 5-aza further reactivates the conversion
of ERa from ERa-negative to ERa-positive in MDA-
MB-231 cells. More strikingly, we found that EGCG
treatment can induce significant effects on cellular
growth inhibition and a prominent synergistic ERa re-
expression when combined with TSA as compared to
combination with 5-aza (Figures 1B and 1E). We also
performed western-blot assays to detect the protein
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cells (Figure 1F). Our results indicated that only com-
bined treatment of EGCG and TSA can induce signifi-
cant expression of ERa protein, which was consistent
with our previous results. In summary, these results sug-
gest that histone modification mechanisms may play a
more important role in EGCG induced-ERa reactivation
than DNA methylation in ERa-negative breast cancer
cells.
EGCG and TSA sensitized ERa-negative breast cancer cells
to E2 and tamoxifen through inducing ERa reactivation
According to our aforementioned observation that
EGCG combined with TSA leads to synergistic
Figure 1 EGCG and TSA synergistically induced ERa re-expression in ERa-negative MDA-MB-231 breast cancer cells. A) Graphic
presentation of dose-dependent cellular growth inhibition by EGCG treatment. MDA-MB-231 cells were exposed to various concentrations of
EGCG (0, 5, 10, 25 and 50 μM) for 3 days. B) Effects of cellular viability by the combined treatment of EGCG with 5-aza (left) and TSA (right). The
MDA-MB-231 cells were treated with or without either 10 μM EGCG or 2 μM 5-aza and 100 ng/ml TSA alone or together for 3 days. C) EGCG
induced ERa re-expression in ERa-negative breast cancer cells. The MDA-MB-231 cells were treated with various concentrations of EGCG as
described above. D) EGCG induced maximal ERa re-expression at a concentration of 10 μM. The MDA-MB-231 cells were treated with additional
concentrations of EGCG (7.5, 15 and 20 μM) to further determine the optimal concentration of EGCG on ERa reactivation. E) EGCG in
combination with 5-aza (left) and TSA (right) enhances ERa transcription. Combination treatment was performed as described above.
Quantitative real-time PCR was performed to measure relative transcription of ERa. Data are in triplicate from three independent experiments
and were normalized to GAPDH and calibrated to levels in untreated samples. Bars, SD; *, P < 0.05, * * P < 0.001, significantly different from
control. F) ERa protein expression with the treatment of EGCG or TSA alone or combination. MDA-MB-231 cells were treated with EGCG or TSA
alone or in combination and MCF-7 cells served as positive control.
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cancer cells, we next sought to investigate whether this
effect could alter ERa-dependent cellular responsiveness
either to the ligand activator, 17 b-estradiol (E2), or the
antagonist, tamoxifen. The effects of E2 are supposed to
stimulate cellular proliferation mediated through ligand-
receptor activated downstream growth-promoting genes
[2], whereas, tamoxifen, acting as an antiestrogen by
competing with estrogen for binding to ER, will lead to
cell growth arrest [23,24]. We therefore investigated the
changes in cellular viability as well as the expression of
the ERa-responsive downstream gene, progesterone
receptor (PGR), in ERa-negative MDA-MB-231 breast
cancer cells with treatments of EGCG and TSA alone or
together. ERa-positive MCF-7 breast cancer cells served
as a positive control. As shown in Figures 2A and 2B,
MCF-7 cells show a good response to E2 as well as
tamoxifen, whereas untreated MDA-MB-231 cells have
no response to these two compounds in terms of cellu-
lar growth and PGR expression. Treatments with either
EGCG or TSA alone did not induce significant cellular
growth changes and PGR response which is likely due
to the limited increased level of ERa expression in the
MDA-MB-231 cells. By contrast, cellular growth and
downstream PGR expression in ERa-negative MDA-
MB-231 cells were significantly changed by combination
treatment with EGCG and TSA in a manner similar to
ERa-positive MCF-7 cells in response to E2 or tamoxi-
f e na ss h o w ni nF i g u r e s2 Aa n d2 B .T h e s er e s u l t si n d i -
cated that the combination of EGCG and TSA can
induce functional ERa re-expression and re-sensitize
ERa-negative breast cancer cells to E2 activator and
tamoxifen antagonist, which could provide an extremely
important clinical implication in potential application of
green tea EGCG with HDACs inhibitors in future thera-
peutic strategies for hormone-resistant breast cancer.
EGCG and TSA caused histone modification changes in
the promoter region of ERa
Our studies have shown that treatment with the green
tea polyphenol, EGCG, combined with HDAC inhibitor,
TSA, can significantly reactivate ERa-responsive signal
transduction due to a synergistic effect on ERa re-
expression in ERa-negative MDA-MB-231 cells, suggest-
ing a potential important role of histone modification in
ERa regulation. Therefore, we conducted our subse-
quent experiments to investigate whether these com-
pounds elicit any effect on histone remodeling.
Histone modification, acting as the primary mechanism
of epigenetic control, exhibits various modification pat-
terns on the histone molecular tail, among which histone
acetylation and methylation are the most important his-
tone modifications that play important roles in gene reg-
ulation [25]. To explore whether these chromatin
markers affect ERa gene expression in response to
EGCG, we performed ChIP assays to analyze the promo-
ter of the ERa gene by using antibodies for both tran-
scriptionally active (acetyl-H 3 ,a c e t y l - H 3 K 9 ,a c e t y l - H 4
and dimethyl-H3K4) and inactive (trimethyl-H3K9) mar-
kers of chromatin. We found that EGCG treatment can
increase enrichment of three histone acetylation chroma-
tin markers, acetyl-H3, acetyl-H3K9, acetyl-H4 (espe-
cially in the histone H3 molecule), suggesting the EGCG-
induced histone acetylation alteration plays an important
role in ERa reactivation (Figures 3A and 3B). Further-
more, EGCG increased the binding of dimethyl-H3K4, a
Figure 2 Treatment with EGCG and TSA retrieved responsiveness to E2 and tamoxifen in ER-negative cells. A) Cellular viability in
response to E2 and tamoxifen. B) The expression of PGR, an ERa target gene, in response to E2 and tamoxifen. EGCG and/or TSA-pretreated
MDA-MB-231 cells were treated with or without 10 nM of E2 or 1 μM tamoxifen for 2 days. MCF-7 cells served as a positive control. Cells were
harvested at the indicated time periods and assessed for cellular viability and PGR expression, respectively. Cellular viability was measured by
Trypan blue exclusion assay. PGR expression was detected by quantitative real-time PCR. Data were obtained from three independent
experiments and normalized to GAPDH and calibrated to levels in samples without treatment of E2 and tamoxifen. Bars, SD; *, P < 0.05,
significantly different from control.
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decreased the binding of the repressor, trimethyl-H3K9,
in the ERa promoter leading to ERa reactivation. In
addition, histone remodeling changes were more promi-
nent when EGCG was combined with TSA than either
treatment alone, which is consistent with our aforemen-
tioned findings indicating that the presence of TSA
greatly enhanced strengthens EGCG-induced histone
remodeling leading to a synergistic change in ERa
expression. Collectively, these results suggest that EGCG
can modulate histone patterns in the ERa promoter
especially when it is combined with TSA, which results
in ERa reactivation in ERa-negative breast cancer cells.
Global alterations of epigenetic enzymatic activity in
response to EGCG
To further interpret the mechanisms of epigenetic mod-
ulations on EGCG-induced ERa re-expression in ERa-
negative breast cancer cells, we assessed the histone
acetylation-related enzymatic activities including the
activities of histone acetyltransferases (HATs) and dea-
cetylases (HDACs). As shown in Figures. 3C and 3D,
both EGCG and TSA acting alone can significantly acti-
vate HATs activity by 7.23 (p < 0.05) and 10.03 fold
(p < 0.01) in MDA-MB-231 cells, while inhibiting
HDACs activities by 1.2 and 1.38 fold, respectively. The
significantly altered HATs and HDACs activities by
Figure 3 Alteration of histone modulation of the ERa promoter and histone acetylation-related enzymatic activities. A) Histone
modification patterns were analyzed by ChIP assay. Representative photograph from an experiment was repeated in triplicate. B) Histone
modification enrichment in the ERa promoter was calculated from the corresponding DNA fragments amplified by ChIP-PCR as shown above.
MDA-MB-231 cells were treated as described previously and analyzed by ChIP assays using chromatin markers including acetyl-H3, acetyl-H3K9,
acetyl-H4, dimethyl-H3K4, trimethyl-H3K9 and mouse IgG control in the promoter region of ERa. MCF-7 cells served as a positive control. Inputs
came from the total DNA and served as the same ChIP-PCR conditions. DNA enrichment was calculated as the ratio of each bound sample
divided by the input while the untreated MDA-MB-231 control sample is represented as 1.0. Columns, mean; Bars, SD. C) and D) Histone
acetyltransferase (HATs) and Histone deacetylases (HDACs) activities in MDA-MB-231 cells. Nuclear proteins of MDA-MB-231 cells were extracted
after the treatment as described above. The HATs and HDACs activity assays were performed according to the manufacturer’s protocols. The
values of enzymatic activities of HATs and HDACs are the means of three independent experiments. Columns, mean; Bars, SD; *, P < 0.05, * * P <
0.001, significantly different from control.
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promoter resulting in ERa reactivation. However, the
enzymatic alteration of HATs and HDACs were more
pronounced (by 13.82 and 1.76 fold, respectively) in
response to combination treatment with EGCG and
TSA compared with either treatment alone. These
results may better explain our previous results showing
that the combination of EGCG and TSA can affect ERa
expression more than EGCG or TSA acting alone, due
to a more efficient epigenetic response induced by the
EGCG green tea polyphenol combined with TSA. Taken
together, our results further indicated that EGCG can
affect ERa expression in ERa-negative breast cancer
cells through influencing epigenetic mechanisms and
this effect was strengthened in the presence of TSA, a
deacetylation inhibitor.
DNA methylation status of ERa promoter by EGCG
treatment
It has been known that more than 25% of ERa-negative
breast cancer cells have aberrant methylation status in
the ERa promoter suggesting that DNA methylation
plays an important role in regulating ERa expression. In
addition, Fang et al have reported that EGCG can inhi-
bit DNA methyltransferase (DNMTs) directly and indir-
ectly [18,19]. We therefore hypothesized that green tea
EGCG may affect DNA methylation status of the ERa
promoter leading to ERa re-expression in ERa-negative
breast cancer cells. To elucidate the effects of methyla-
tion on the hTERT promoter, we examined the methyla-
tion status of the ERa promoter region from -66 to -356
covering 29 CpG dinucleotides and various overlapping
transcription factor binding sites. We then used bisul-
fite-sequencing analysis to detect the ERa methylation
patterns of EGCG-treated MDA-MB-231 cells. ERa-
positive MCF-7 and untreated ERa-negative MDA-MB-
231 breast cancer cells served as controls. As shown in
Table 1, the ERa promoter region of MCF-7 cells main-
tained an unmethylated status rendering ERa open
expression, whereas the ERa promoter of the untreated
MDA-MB-231 cells was hypermethylated leading to
silencing of ERa expression. However, there was no sig-
nificant change in methylation status of the ERa promo-
ter between untreated MDA-MB-231 control cells with
44.8 ± 3.75% methylated CpG island and EGCG-treated
MDA-MB-231 cells with 48.2 ± 4.45% methylated CpG
island (Table 1), which indicated that DNA methylation
m a yp l a yal e s sr o l ei nE G C G - m e d i a t e dE R a re-expres-
sion. Previous studies indicated that treatment with the
DNMTs inhibitor, 5-aza, can lead to demethylation in
the ERa promoter [8]. These results may explain our
aforementioned findings showing that the combination
of EGCG with 5-aza has less effect on ERa expression,
which may be due to lack of effect of EGCG on DNA
methylation in the ERa promoter. These results further
suggested that histone modification is of much greater
importance than DNA methylation in regulating ERa
expression in response to green tea EGCG.
EGCG treatment altered the binding of transcription
repressor complex to the ERa promoter
Many studies have shown that transcription factors play a
crucial role in regulating gene expression by interacting
with epigenetic modulators. For example, HDAC/
DNMT1 involves a series of gene silencing through
recruiting transcriptional repressors to the gene promo-
ter [26,27]. Moreover, histone methyltransferase,
SUV39H1, is another important epigenetic factor for
transcriptional silencing [28]. A recent study has shown
that a multimolecular complex, pRb2/p130-E2F4/5-
HDAC1-DNMT1-SUV39H1, binding to the ERa promo-
ter, is associated with ERa transcriptional repression in
ERa-negative breast cancer MDA-MB-231 cells [29].
Further, the switching of DNMT1 to p300 in this com-
plex will induce ERa transcription. We therefore sought
to explore whether EGCG can affect the binding of this
transcriptional complex to the ERa promoter. Using
chromatin immunoprecipitation (ChIP) techniques, we
observed that EGCG treatment can significantly decrease
the binding of all the transcription factors of the repres-
sor complex to the ERa promoter and this effect was
greater for transcription factors such as SUV39H1 and
Rb/p130 when EGCG was combined with TSA suggest-
ing SUV39H1 and Rb/p130 may play an important role
to assemble other transcription factors to the ERa pro-
moter (Figures 4A and 4B). In particular, EGCG alone
can induce a pronounced reduction of binding of
HDAC1 and DNMT1 by 20 and 12.5 fold, respectively,
further suggesting that epigenetic control plays a crucial
role in EGCG-induced ERa reactivation. However, no
difference has been found in the binding alteration of
p300 in response to EGCG and/or TSA treatment indi-
cating an alternative mechanism may involve p300-
induced estrogen gene activation. To identify the direct
mechanism of EGCG on ERa transcription regulation,
Table 1 DNA methylation status of the ERa promoter
Cells Percentage of methylated
CpG island in the ER
promoter (%)
P value compared with
untreated MDA-MB-231
cells
MCF-7 0 -
Untreated
MDA-MB-
231
44.8 ± 3.75* -
EGCG-
treated
MDA-MB-
231
48.2 ± 4.45* 0.36
* Standard deviations.
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expression of the related epigenetic factors induced by
EGCG. As indicated in Figure 4C, the protein level of
HDAC and SUV39H1 were decreased significantly,
whereas p300 was increased prominently by EGCG, espe-
cially when EGCG was combined with TSA. However, no
significant changes were found in protein levels of
DNMT1 (data not shown), which may explain the less
response of DNA methylation alteration in the ERa pro-
moter. Collectively, these results suggest that the binding
alterations of repressor complex to the promoter and/or
direct expression regulation of key epigenetic factors
contributed to the reactivation of ERa by the botanical
compound EGCG (Figure 5).
Discussion
The intriguing effects of the bioactive botanic compo-
nent of green tea, EGCG, on cancer chemoprevention
and therapy have received considerable attention [30].
Various molecular mechanisms have been proposed
involving EGCG-induced inhibitory effects on many
types of cancers including breast cancer. Clinical prog-
nosis and subsequent therapeutical strategies of malig-
nant breast cancer rely on the expression of an
important growth factor receptor, the nuclear estrogen
receptor a (ERa) [1]. Therefore, ERa-positive breast
cancer patients receiving standard endocrine therapy by
the use of the anti-estrogen drug such as tamoxifen, will
generally have a better prognosis [4,24]. However, ERa-
negative tumors display resistance to anti-hormone ther-
apy due to the lack of targeting-directed therapies and
this form of tumor is more aggressive and renders a
poorer prognosis [23,24]. Thus, new therapies or strate-
gies for sensitization of ERa-negative tumors to endo-
crine treatment are urgently required.
In the present study, we provided evidence that EGCG
can induce re-expression of endogenous estrogen recep-
tor a (ERa)i nE R a-negative MDA-MB-231 breast
Figure 4 EGCG and TSA alters the binding of transcriptional repressor complex to the ERa promoter. A) MDA-MB-231 cells were treated
with EGCG and/or TSA as described previously and analyzed by ChIP assay together with untreated control cells. Chromatin DNA from MCF-7
and MDA-MB-231 cells was immunoprecipitated with antibodies against proteins of the ERa transcriptional repressor complex including HDAC1,
SUV39H1, DNMT1, E2F-4, Rb/p130 and p300 together with mouse IgG control. MCF-7 cells served as a positive control. Inputs came from the
total DNA and served as the same ChIP-PCR conditions. The purified ChIP-DNA was amplified by PCR with the use of ERa promoter primers.
Enrichment values were quantified and normalized to the corresponding inputs while the untreated MDA-MB-231 control sample is represented
as 1.0. Representative photograph shown from three independent experiments. B) ChIP data were calculated from the corresponding DNA
fragments amplified by ChIP-PCR; columns, mean; bars, SD. C) The protein levels of epigenetic regulators, HDAC1, SUV39H1 and p300, were
determined by western-blot analysis. MCF-7 and MDA-MB-231 cellular proteins were extracted after corresponding treatments. Protein lysates (50
μg) were resolved on 12% SDS-PAGE, transferred onto nitrocellulose membrane, and probed with antibodies against HDAC1, SUV39H1 and p300.
Membranes were re-probed with anti-GAPDH antibody to ensure equal loading. Representative photograph shown from the experiments
repeated in triplicate.
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Page 9 of 12cancer cells. For the first time, our results clearly show
that this functional ERa reactivation by EGCG treat-
ment is at least partly regulated via epigenetic mechan-
isms, especially through chromatin remodeling. We also
found that this effect was synergistically enhanced when
EGCG was combined with the deacetylation inhibitor,
TSA, indicating histone modification plays an important
role in EGCG-induced ERa reactivation. Furthermore,
EGCG was found to influence the assembling of tran-
scription repressors complex in the promoter region of
ERa leading to ERa re-expression in ERa-negative
breast cancer cells. Therefore our results indicate that
green tea EGCG can sensitize ERa-negative breast can-
cer cells to respond to conventional anti-hormone ther-
apy through reactivating ERa, which could provide a
new avenue for therapeutical strategies of hormone-
resistant breast cancer.
A number of findings have demonstrated that epige-
netic regulation is one of the most important molecular
mechanisms that result in the absence of estrogen
receptor a (ERa) in hormone-resistant breast cancer
cells [6-9]. Previous studies have shown that applying
different epigenetic-related enzymatic inhibitors such as
the HDAC inhibitor, TSA, and the DNMT1 inhibitor,
5-aza, can reactivate functional ER expression suggesting
that epigenetic mechanisms play a crucial role in ER
transcription regulation [8].R e c e n t l y ,e x t e n s i v es t u d i e s
have focused on a dietary component, EGCG, the most
abundant catechin in green tea beverages, in regard to
its chemopreventive and anticancer properties. Various
mechanisms have been demonstrated for the anticancer
property of EGCG including inhibition of cellular oxida-
tive stress, inhibition of angiogenesis, and regulation of
signal transduction. However, Fang et al. have found
that EGCG can inhibit DNMT activity directly and
indirectly, thereby leading to demethylation and reacti-
vation of methylation-silenced tumor suppressor genes
such as p16
INK4a, RARb and MGMT in human esopha-
geal cells [18,19]. Moreover, our previous studies also
showed that EGCG treatment can inhibit telomerase
activity through epigenetic regulation of the hTERT
(human telomerase reverse transcriptase) gene [17].
Taken together, these results indicate that EGCG may
affect epigenetic control of transcription regulation in
certain epigenetic-sensitive tumor-related key genes
such as the estrogen receptor gene in breast cancer cells.
Figure 5 Schematic representation of a mechanism of EGCG-induced ERa reactivation in ERa-negative breast cancer cells.I nt h i s
model, EGCG and TSA can affect chromatin modifications as well as the binding alteration of a transcription repressor complex, Rb/p130-E2F4/5-
HDAC1-DNMT1-SUV39H1, to the ERa promoter, resulting in ERa reactivation in ERa-negative breast cancer cells.
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tively low concentration of EGCG treatment could
i n d u c eap r o n o u n c e dE R a re-expression in ERa-nega-
tive breast cancer cells suggesting that EGCG can reacti-
vate the estrogen signal pathways via regulating ERa
re-expression. More importantly, administration of
EGCG has shown a huge chemopreventive potential on
hormone-resistant breast cancer simply by drinking
green tea to maintain a low level of EGCG in serum
[31]. Epigenetic mechanisms play an important role in
ERa regulation. However, we only observed a synergistic
effect on reactivating functional ERa expression when
EGCG was combined with the HDAC inhibitor, TSA,
rather than with the DNMT inhibitor, 5-aza, indicating
histone modification may play a more important role in
EGCG-induced ERa reactivation than DNA methylation.
This hypothesis has been confirmed by our results
showing that various chromatin markers were dramati-
cally altered in the ERa promoter by EGCG treatment
accompanied by corresponding alterations in the activ-
ities of histone modification-related enzymes such as
HDACs and HATs in ERa-negative breast cancer cells.
Consistently, we did not find any changes of DNA
methylation patterns in the ERa promoter and the pro-
tein level of DNMT1 by EGCG treatment. However, a
decreased binding of DNMT1 in the ERa promoter by
EGCG treatment shown in Figures 4A and 4B may bet-
ter explain a minor increased ERa expression when
EGCG was combined with 5-aza compared to treatment
with EGCG or 5-aza alone as indicated in Figure 1E.
Taken together, our results showing a minor role of
DNA methylation in EGCG-induced ERa reactivation
do not contradict the demethylation nature of EGCG in
previous studies, but rather highlight the gene and site-
specificity of EGCG treatment on global DNA methyla-
tion patterns [32]. It also elicits an interesting possibility
that consumption of green tea and cruciferous vegeta-
bles such as brocoli, which are abundant in natural
EGCG and the deacetylation agent such as sulforaphane
[33,34], respectively, may result in a better chemopre-
ventive outcome of breast cancer based on our current
studies.
Abundant evidence has shown that gene transcription
in eukaryotic cells is strongly influenced by interaction
between transcription factors regulation and the modifi-
cation of chromatin in the promoter regions of certain
genes. In particular, epigenetic-related enzymes can not
only affect the chromatin state, but also further influ-
ence the accessibility of the transcriptional machinery,
resulting in gene activation or repression [26-28]. A
transcriptional complex model has been reported invol-
ving ERa regulation in breast cancer cells by Macaluso
et al [29], we then tested this concept in ERa-negative
breast cancer cells by the treatment with EGCG and
TSA alone or together. Our results revealed that EGCG
can affect the binding of a multimolecular repressor
complex, Rb/p130-E2F4/5-HDAC1-DNMT1-SUV39H1,
to the ERa promoter, leading to ERa reactivation (Fig-
ure 5). This result thereforep r o v i d e sak e ym e c h a n i s m
that modulates a crosstalk of both genetic and epige-
netic signal transduction in ERa expression by EGCG as
well as EGCG combined with a HDAC inhibitor.
Collectively, our studies investigate the basic epige-
netic mechanisms by which green tea EGCG induces
functional ERa reactivation in ERa-negative breast can-
cer cells. We found a relatively low concentration of
EGCG could re-sensitize hormone-resistant breast can-
cers cells to the hormone antagonist, tamoxifen, by re-
expression of functional ERa in ERa-negative breast
cancer cells. In addition, EGCG-induced chromatin
remodeling and accompanied binding changes of the
transcriptional complex in the ERa promoter contribute
to ERa reactivation. More importantly, these aforemen-
tioned effects were consolidated by combining EGCG
with the deacetylation inhibitor, TSA, suggesting chro-
matin modulation plays a crucial role in EGCG-induced
ERa reactivation.
Conclusions
In conclusion, our findings provide important observa-
tions relevant to clinical prevention and therapeutic
application for de novo hormone-resistant patients. It
provides an alternative clinical approach of the endo-
crine therapy targeting ERa in ERa-negative breast can-
cer patients through consumption of the natural dietary
ingredient, EGCG. In addition, the elucidation of ERa
regulation by combination treatment of EGCG with
other epigenetic agents including several HDAC inhibi-
tors currently under clinical trial could help in designing
novel combined therapeutic and innovative drug delivery
strategies. Future efforts aimed at determining the
appropriate administration of EGCG and elucidating the
further anti-cancer mechanisms are needed in vivo.
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